SLDB

Solid BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$11.50

+74.8% vs current

Most likely

Base case

Probability

Target price

$8.60

+30.7% vs current

B-

Bear case

Probability

Target price

$5.50

-16.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Primary-source evidence supports a cautious monitoring setup rather than a high-conviction bullish call: Solid has real 2026 operating milestones and better runway after the March financing, but the stock still depends heavily on near-term Phase 3 execution and regulatory clarity around SGT-003 in a Duchenne field that now has clearer direct comparators. Deterministic priors are negative and catalyst density is still light, so sentiment stays restrained despite multiple upcoming checkpoints.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-04-30eventFirst Phase 3 IMPACT DUCHENNE dosingHigh impact

Management said it anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026, which is the clearest near-term operating checkpoint for SGT-003 execution after FDA alignment on study design [#PR-2026-03-19] [#PR-2026-02-09].

2026-06-30eventFDA follow-up on accelerated approval pathwayHigh impact

Solid said additional FDA meetings are planned in H1 2026 to seek guidance on a potential accelerated approval pathway for SGT-003; constructive feedback would matter more than generic trial progress because it could shape the registrational path [#PR-2026-03-19] [#PR-2026-02-09].

2026-06-30catalystRunway extension lowers immediate financing pressureHigh impact

March 2026 business updates and financing materials indicate $187.9 million of cash at December 31, 2025, a completed $240 million private placement, and expected runway into H1 2028, reducing near-term financing stress but not eliminating later dilution risk as clinical spend ramps [#PR-2026-03-19] [#PR-2026-03-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology